Growing at an annualized rate of over 16.5%

Bhavya kamboj

333
views

Growing at an annualized rate of over 16.5%

Theapproval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased theinterest of pharma stakeholders in cell therapies; further, owing to thetechnical challenges in this field, outsourcing manufacturing operations hasbecome a necessity

Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030” report to its list ofofferings.

Owingto various reasons, the demand for cell therapies is anticipated to increase overthe coming years. Therefore, both therapy developers and contract serviceproviders may need to strengthen their capabilities and expand availablecapacity. In this context, automation is expected to be a key enabler withinthe cell therapy manufacturing and contract services industry.

To order this 550+ pagereport, which features 160+ figures and 250+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

KeyMarket Insights

Morethan 160 organizations claim to be engaged in cell therapy manufacturing

Themarket landscape is dominated by industry players, representing more than 60%of the total number of stakeholders. Amongst these, over 55 are large ormid-sized firms (having more than 50 employees).

100+ players focused on T-celland stem cell therapies

Mostof these players are focused on manufacturing T-cell therapies, including CART,TCR or TILs. It is worth highlighting that more than 35 organizations claim tohave necessary capabilities for the manufacturing of both types of therapies.

Presently, 70+ companies havecommercial scale capacity

Asmajority of the cell therapy products are in clinical trials, the demand ishigh at this scale. However, it is worth noting that several players (~50%)have already developed commercial scale capacity for cell therapies.

Europe is currently considered acurrent hub for cell therapy production

Morethan 220 manufacturing facilities have been established by various players,worldwide; of these, 35% are in Europe, followed by those based in NorthAmerica. Other emerging regions include Australia, China, Japan, Singapore,South Korea and Israel.

50+ facility expansions reportedbetween 2015-2019

Morethan 85% of the expansions are related to setting up of new facilities acrossdifferent regions. Maximum expansion activity was observed in the US and incertain countries within the Asia Pacific regions.

20+companies offer automated solutions to cell therapy developers

Playersthat claim to offer consultancy services related to automation include (inalphabetical order) Berkeley Lights, Cesca Therapeutics, Ferrologix, FluDesignSonics, GE Healthcare and Terumo BCT. Further, we identifiedplayers, namely (in alphabetical order) Fraunhofer Institute forManufacturing Engineering and Automation IPA, Invetech, KMC Systems, MayoClinic Center for Regenerative Medicine and RoosterBio, that offer consultancysolutions related to automation.

Partnershipactivity has grown at an annualized rate of 16%, between 2014 and 2018

Morethan 200 agreements have been inked in the last 5 years; majority of these werefocused on the supply of cell-based therapy products for clinical trials. Otherpopular types of collaboration models include manufacturing process developmentagreements (16%), services agreements (12%) and acquisitions (10%).

By2030, developed geographies will capture over 60% of the market share

AsiaPacific is anticipated to capture the major share (~36%) of the market by 2030.It is also important to highlight that financial resources, technical expertiseand established infrastructure is likely to drive cell therapy manufacturingmarket in Europe, which is estimated to grow at a CAGR of ~26%.

Torequest a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

KeyQuestions Answered

§ What is the global demand for cell-based therapies?

§ Who are the key manufacturers (industry / non-industry) ofcell-based therapies, across the world?

§ What are the major recent developments (such aspartnerships and expansions) in this industry?

§ What kind of partnership models are commonly adopted bystakeholders in this domain?

§ What is the current, installed contract manufacturingcapacity for cell therapies?

§ What are the key factors influencing the make(manufacture in-house) versus buy (outsource) decision related to celltherapies?

§ What are the key parameters governing the cost of celltherapy manufacturing?

§ What are important technology platforms (available / underdevelopment) for cell therapy development and manufacturing?

§ Whatare the key drivers and growth constraints in cell therapy manufacturing market?

§ How is the current and future market opportunity likely tobe distributed across key market segments?

The USD 11 billion (by 2030) financial opportunitywithin the cell therapy manufacturing market has been analyzed across thefollowing segments:

§ Typeof therapy

§ T-celltherapies (CAR-T therapies, TCR therapies, TIL therapies)

§ Dendriticcell therapies

§ Tumorcell therapies

§ NKcell therapies

§ Stemcell therapies

§ Source of cells

§ Autologous

§ Allogeneic

§ Scaleof operation

§ Clinical

§ Commercial

§ Purposeof manufacturing

§ Contract manufacturing

§ In-house manufacturing

§ Keygeographical regions

§ North America

§ Europe

§ Asia Pacific

§ Rest of the world

Thereport features inputs from eminent industry stakeholders, according to whom themanufacturing of cell therapies is largely being outsourced due to exorbitantcosts associated with the setting-up of in-house expertise. The report includesdetailed transcripts of discussions held with the following experts:

§ Victor Lietao Li (Co-Founder and Chief Executive Officer,Lion TCR)

§ Tim Oldham (Chief Executive Officer, Cell Therapies)

§ Gerard MJ Bos (Chief Executive Officer, CiMaas)

§ Wei (William) Cao (Chief Executive Officer, GracellBiotechnologies)

§ Troels Jordansen (Chief Executive Officer, GlycostemTherapeutics)

§ Arik Hasson (Executive VP Research and Development, Kadimastem)

§ Gilles Devillers (General Manager, Bio Elpida)

§ Arnaud Deladeriere (Manager, Business Development &Operations-cGMP Manufacturing Unit, Center of Excellence for Cellular Therapy /C3i)

§ Brian Dattilo (Manager of Business Development, WaismanBiomanufacturing)

§ Fiona Bellot (Business Development Manager, RoslinCT)

§ Mathilde Girard (Department Leader, Cell Therapy Innovationand Development, YposKesi)

§ David Mckenna (Professor and American Red Cross Chair inTransfusion Medicine, University of Minnesota)

Theresearch covers profiles of key players (industry and non-industry) that offermanufacturing services for cell-based therapies, featuring a company overview, informationon manufacturing facilities, and recent collaborations.

§ BioNTech Innovative Manufacturing Services

§ Cell Therapies

§ Cell and Gene Therapy Catapult

§ Center for Cell and Gene Therapy, Baylor College ofMedicine

§ Centre for Cell Manufacturing Ireland, National Universityof Ireland

§ Clinical Cell and Vaccine Production Facility, Universityof Pennsylvania

§ Cognate BioServices

§ FUJIFILM

§ Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital

§ Hitachi Chemical

§ KBI Biopharma

§ Laboratory for Cell and Gene Medicine, Stanford University